Andreas D. Meid

Post-doctoral researcher in Clinical Pharmacology & Pharmacoepidemiology

Heidelberg University

Biography

Andreas D. Meid is a post-doctoral researcher and private lecturer in the Dept. of Clinical Pharmacology & Pharmacoepidemiology at Heidelberg University Hospital. Research interests include exploring (pharmacoepidemiologic) databases to determine individualized treatment recommendations using predictive modeling. He collaborates with clinicians and methodologists and applies cutting-edge methods of parametric statistical modeling and machine learning. In addition to leading the Pharmacoepidemiology group, he is also extensively involved in various quantitative pharmacology and pharmacometrics analyses. In doing so, he aims to quantify benefits and risks of drugs in regular and special populations (e.g., older or pediatric patients).

Interests

pharmacometrics, population pharmacokinetics / QSP modeling, biostatistics
pharmacoepidemiology for real-world evidence on effectiveness and safety
personalized decision support from predictive modeling and machine learning

Education

Habilitation in Clinical Pharmacology and Pharmacoepidemiology, 2022
Medical Faculty Heidelberg
Doctorate (Dr. sc. hum) in Clinical Pharmacology, 2017
Heidelberg University, Dept. of Clinical Pharmacology and Pharmacoepidemiology
MSc in Medical Biometry and Biostatistics, 2013
Heidelberg University, Institute of Medical Biometry and Informatics
Approbation of Pharmacy, 2008
Heidelberg University, Institute of Pharmacy and Molecular Biotechnology

Skills and interests

R

Proficient R user including interfaces to other programs (e.g., Monolix)

Statistics

Trained statistician

Data science

Follower of Open Data philosophy

Publishing

Passionate writer

Peer-reviewing

Dedicated peer-reviewer

Bike

Cycle to work!

Experience

Post-doctoral researcher, Head of Pharmacoepidemiology section

Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology

2017 – Present Heidelberg

Responsibilities include:

Planning and analysis of non-interventional and interventional studies
Explanatory pharmacoepidemiology research yielding real-world evidence
Predictive research for individualizing treatment benefit and risks
Electronic expert systems supporting individualized treatment rules

Research Scientist

Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology

2014 – 2017 Heidelberg

Responsibilities include:

Pharmacoepidemiological research on medication underuse, overuse, and misuse
Statistical consulting and education
Electronic decision support
Pharmacological counselling

Pharmacist and extra-occupational graduate student

Apotheke am Markt (Mannheim) and Merck Serono (Darmstadt, July 2012 to December 2012)

2010 – 2013 Mannheim, Darmstadt

Competences include:

Training as qualified statistician
Statistical focus on survival analysis, multiple comparison procedures, (nonlinear) regression models, variable selection, prediction model performance
Medical expertise in Oncology
Modeling and Simulation expertise in pharmacokinetics with focus on graphical model diagnostics

Deputy director (chief representative on-site)

Bahnhof-Apotheke Mannheim, Ralf Busch e.K.

2008 – 2010 Mannheim

Responsibilities include:

Quality and failure management
Project management
Team leading

Projects

TREND-REVIVAL

Research grant from the 2024 iDEA-iTECH Awards EU.

MAGIC-BULLET

Research grant from the 2023 iDEA-iTECH Awards EU.

Teaching

Overview of courses.

Featured Publications

Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines

Applying generalisability and transportability analyses to realistic synthetic data in situations where no real-world data (RWD) are available (eg, because a drug has only recently been marketed) can help to inform which patient can benefit from the new drug. Generalisability and transportability analyses analyses should be considered as a statistical technique to provide valuable insights for clinical decision-making and to guide future trials, and under no circumstances as a replacement for randomised controlled trials (RCTs) with a more diverse trial population. It will be interesting to see how the proposed approach works in practice in the future, whether in the chosen example of a new antibody-drug conjugate for breast cancer treatment or in other conceivable situations where knowing the patient benefit in routine care is particularly important.

Ignacio Leiva-Escobar, Camilo Scherkl, Walter E Haefeli, Andreas D. Meid

PDF DOI

Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of Spironolactone

This pilot case shows how a repurposed QSP model could contribute to informed decision-making in everyday clinical practice. With increasing knowledge in the actual patient course, the model updates itself in a Bayesian approach to predict, in our case, the expected potassium course for the next 24 hours, which also takes planned drug administrations into account. Thus, the model prediction could give reason to preemptively modify potassium supplementation, to modify comedication affecting potassium concentrations, to reduce the spironolactone dose or, for safety, to arrange for additional laboratory measurements. Our use case presented here shows a proof-of-principle that this is also conceptually possible with mechanistic QSP models after being operationalized for this purpose.

Andreas D. Meid, Camilo Scherkl, Michael Metzner, David Czock, Hanna M Seidling

PDF DOI

Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition

We conclude that, first, rifabutin can enhance absorption (indicated by higher Cmax) of P-gp substrate victim drugs by inhibiting intestinal P-gp. This might be most important during the initial phase of combination therapy. Second, rifabutin is in fact an inducer of drug-metabolizing enzymes and drug transporters after repetitive administration, potentially leading to lowered victim drug exposure. However, P-gp inhibition can still overlap with (or even exceed) induction effects, especially when the victim drug and rifabutin (perpetrator) are administered simultaneously, leading to high intestinal rifabutin inhibitory drug concentrations. In general, we would also like to emphasize how important it is to complement empirical results with mechanistic analyses. In this regard, the important work of Kawuma and co-workers was a very valuable contribution.

Dirk Theile, Julie Nilles, Andreas D. Meid

PDF DOI

Recent Publications

Quickly discover relevant content by filtering publications.

Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines

Ignacio Leiva-Escobar, Camilo Scherkl, Walter E Haefeli, Andreas D. Meid

PDF DOI

Towards a prescribing monitoring system for medication safety evaluation within electronic health records: a scoping review

Camilo Scherkl, Theresa Dierkes, Michael Metzner, David Czock, Hanna M Seidling, Walter E Haefeli, Andreas D. Meid

PDF DOI

Testing Higher Doses of Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia: An Open-Label Dose-Finding Phase 1b Clinical Trial-Sildenafil Administration to Treat Neonatal Encephalopathy-Study 02

Pia Wintermark, Anie Lapointe, Gabriel Altit, Robin Steinhorn, Emmanouil Rampakakis, Andreas D. Meid, Juergen Burhenne, Gzona Bajraktari-Sylejmani, May Khairy, Marie-Therese Adamo, Guillaume Gilbert, Daniela Toffoli, Samara Zavalkoff, Thuy Mai Luu, Elizabeth Hailu, Walter E Haefeli

PDF DOI

See all publications

Andreas D. Meid

Post-doctoral researcher in Clinical Pharmacology & Pharmacoepidemiology

Heidelberg University

Biography

Interests

Education

Skills and interests

R

Statistics

Data science

Publishing

Peer-reviewing

Bike

Experience

Post-doctoral researcher, Head of Pharmacoepidemiology section

Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology

Research Scientist

Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology

Pharmacist and extra-occupational graduate student

Apotheke am Markt (Mannheim) and Merck Serono (Darmstadt, July 2012 to December 2012)

Deputy director (chief representative on-site)

Bahnhof-Apotheke Mannheim, Ralf Busch e.K.

Recent Posts

Quantitative Systems Pharmacology in Oncology

Teaching reproducible research

Projects

TREND-REVIVAL

MAGIC-BULLET

Teaching

Featured Publications

Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines

Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of Spironolactone

Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition

Recent Publications

Contact